JP2022509262A - 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント - Google Patents

乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント Download PDF

Info

Publication number
JP2022509262A
JP2022509262A JP2021530913A JP2021530913A JP2022509262A JP 2022509262 A JP2022509262 A JP 2022509262A JP 2021530913 A JP2021530913 A JP 2021530913A JP 2021530913 A JP2021530913 A JP 2021530913A JP 2022509262 A JP2022509262 A JP 2022509262A
Authority
JP
Japan
Prior art keywords
patient
abemaciclib
dose
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509262A5 (enExample
Inventor
アラガム，ニナ，ケイ．
モリス，チャールズ
Original Assignee
ラジウス ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラジウス ファーマシューティカルズ，インコーポレイテッド filed Critical ラジウス ファーマシューティカルズ，インコーポレイテッド
Publication of JP2022509262A publication Critical patent/JP2022509262A/ja
Publication of JP2022509262A5 publication Critical patent/JP2022509262A5/ja
Priority to JP2025050208A priority Critical patent/JP2025094216A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021530913A 2018-11-30 2019-11-26 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント Pending JP2022509262A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050208A JP2025094216A (ja) 2018-11-30 2025-03-25 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
US62/773,960 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050208A Division JP2025094216A (ja) 2018-11-30 2025-03-25 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント

Publications (2)

Publication Number Publication Date
JP2022509262A true JP2022509262A (ja) 2022-01-20
JP2022509262A5 JP2022509262A5 (enExample) 2022-12-02

Family

ID=68966023

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530913A Pending JP2022509262A (ja) 2018-11-30 2019-11-26 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
JP2025050208A Pending JP2025094216A (ja) 2018-11-30 2025-03-25 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050208A Pending JP2025094216A (ja) 2018-11-30 2025-03-25 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント

Country Status (18)

Country Link
US (3) US20220117963A1 (enExample)
EP (1) EP3886826A1 (enExample)
JP (2) JP2022509262A (enExample)
KR (1) KR20210097170A (enExample)
CN (1) CN113164415A (enExample)
AU (1) AU2019388900B2 (enExample)
BR (1) BR112021010169A2 (enExample)
CA (1) CA3120368A1 (enExample)
EA (1) EA202191165A1 (enExample)
IL (1) IL283502A (enExample)
JO (1) JOP20210125A1 (enExample)
MA (1) MA54293A (enExample)
MX (1) MX2021005876A (enExample)
MY (1) MY209833A (enExample)
PH (1) PH12021551235A1 (enExample)
SG (1) SG11202105455RA (enExample)
UA (1) UA129403C2 (enExample)
WO (1) WO2020112765A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017160990A1 (en) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
JP2018518529A (ja) * 2015-04-29 2018-07-12 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518529A (ja) * 2015-04-29 2018-07-12 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
WO2017160990A1 (en) * 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. Vol.77 Iss.13_Suppl., JPN6023044697, 2017, pages 4160, ISSN: 0005579577 *
CANCER RES., vol. Vol.78 Iss.4_Suppl., JPN6023044696, February 2018 (2018-02-01), pages 4 - 04, ISSN: 0005579578 *
J. CLIN. ONCOL., vol. Vol.35 No.15_suppl., JPN6024052254, 2017, pages 1014, ISSN: 0005579583 *
J. NATL. CANCER INST., vol. 106(5), JPN6024052258, 2014, ISSN: 0005579579 *
MOL. CANCER THER., vol. 17(5), JPN6024052255, May 2018 (2018-05-01), pages 897 - 907, ISSN: 0005579582 *
ONCOTARGET, vol. 8, no. 17, JPN6024052257, 2017, pages 27990 - 27996, ISSN: 0005579580 *
PHYOTHER. RES., vol. 31, JPN6024052256, 2017, pages 1529 - 1538, ISSN: 0005579581 *

Also Published As

Publication number Publication date
US20250268899A1 (en) 2025-08-28
IL283502A (en) 2021-07-29
CA3120368A1 (en) 2020-06-04
JOP20210125A1 (ar) 2019-11-26
KR20210097170A (ko) 2021-08-06
MA54293A (fr) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MY209833A (en) 2025-08-07
BR112021010169A2 (pt) 2021-08-17
SG11202105455RA (en) 2021-06-29
AU2019388900B2 (en) 2025-09-04
MX2021005876A (es) 2021-07-16
US20260014153A1 (en) 2026-01-15
UA129403C2 (uk) 2025-04-16
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
EA202191165A1 (ru) 2021-09-21
US20220117963A1 (en) 2022-04-21
AU2019388900A1 (en) 2021-06-10
EP3886826A1 (en) 2021-10-06
PH12021551235A1 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
US20250268899A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
JP7504097B2 (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
CN120202007A (zh) 用于治疗转移性癌症的与抗血管生成剂组合的plk1抑制剂
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
JP7497353B2 (ja) Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
CA2984357C (en) Methods for treating cancer
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250325